Vaccines Market Research Reports & Industry Analysis
Because of the large number of deadly diseases that have been eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements of the 20th century. Key issues in the global vaccine market today include unequal access to vaccines, supply chain disruptions, the use of vaccines to prevent pandemics and address bioterrorism, technological innovations, and vaccine hesitancy. Learn more about this critical field with the comprehensive selection of vaccine market research reports available on MarketResearch.com.
New Vaccines Market Data and Insights
- Find data on vaccine market size segmented by region, technology, distribution channel, type, route of administration, and disease.
- Gain a deep understanding of vaccine industry dynamics, market structure, growth outlook, and competitive landscape.
- Learn about influential government initiatives and new vaccination technologies that have highly promising results.
Your Source for Expert Data and Analysis
MarketResearch.com is a trusted research partner, backed by over two decades of experience. Our clients include top investment banks, management consulting firms, and leading multinational companies within the Fortune 500. Our team of research specialists is dedicated to guiding you at every step, ensuring you have the resources and insights you need to answer your toughest research questions. Browse our full list of vaccines industry reports today.
Vaccines Industry Research & Market Reports
-
Viral Vector Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
... human cells, have demonstrated notable efficacy against threats like Ebola and COVID-19. According to a recent study by Fairfield Market Research, the viral vector vaccines market is anticipated to grow from US$ 872.4 million in ... Read More
-
Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030
... market is primarily fueled by the escalating incidence of chronic diseases, including cancer, neurodegenerative disorders, and CVDs; this trend underscores the urgent need for novel diagnostic and therapeutic strategies. Exosomes, due to their properties as ... Read More
-
Global Bio-pharma Market 2025-2029
... analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, ... Read More
-
Bovine Mastitis Market, by Type (Clinical Mastitis and Sub-clinical Mastitis), by Product (Antibiotics, Vaccines, Pain Killers, and Others), by Route of Administration (Intra-mammary and Systemic), by Therapy (Lactating Period, Dry Period (Antibiotics, and Teat Sealants)), by End User (Veterinary Centers, Hospital, Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032
... prevalent in dairy cows globally. It's a condition known for causing damage on the dairy industry's profit margin. Mastitis is caused by a huge number of different microorganism species. Viruses, mycoplasmas, fungi, and bacteria are ... Read More
-
North America Healthcare Cold Chain Logistics Market Report by Product (Biopharmaceuticals, Vaccines, Clinical Trials), Segment (Transportation, Packaging, Instrumentation), and Country 2025-2033
... 3.9% during 2025-2033. The increasing cellular therapies and biomarker testing, escalating need to reduce wastage and financial losses, and surging demand for vaccines to treat numerous diseases among individuals represent some of the key factors ... Read More
-
US Healthcare Advertising Market Report by Product Type (Pharmaceuticals (Small Molecule Drugs), Biopharmaceuticals, Vaccines, Over-The-Counter (OTC) Drugs) 2025-2033
... The growing online direct-to-consumer advertising due to the shift in promotional activities towards digital platforms, the augmenting demand to obtain certification and bid for relevant keywords among advertisers, and increased advertising expenditure from healthcare organizations ... Read More
-
mRNA Vaccines and Therapeutics Market Report by Vaccine Type (Self-amplifying mRNA-Based Vaccines, Conventional Non-Amplifying mRNA-Based Vaccines), Treatment Type (Bioengineered Vaccine, Gene Therapy, Gene Transcription, Cell Therapy, Monoclonal Antibody, and Others), Vaccine Manufacturing (In-House, Out-Sourced), Application (Cancer, Infectious Disease, Gene Editing, Protein Replacement), End-User (Hospitals and Clinics, Research Organizations, and Others), and Region 2025-2033
... during 2025-2033. The development and acceptance of mRNA-based vaccines on a global scale, the growing need for quick and adaptable solutions for emerging and re-emerging infectious diseases, and the increasing incidence of cancer and genetic ... Read More
-
Ruminant Vaccines
... CAGR of 6.1% over the analysis period 2024-2030. Modified / Attenuated Live, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$4.0 Billion by the end of ... Read More
-
Monkeypox Vaccine and Treatment
... 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Monkeypox Vaccines, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$107.2 Million by the ... Read More
-
Vaccine Technologies
... CAGR of 8.8% over the analysis period 2024-2030. Live-Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$23.3 Billion by the end of the analysis ... Read More
-
Plant-based Vaccines
... CAGR of 47.8% over the analysis period 2024-2030. Bacterial Vaccines, one of the segments analyzed in the report, is expected to record a 43.0% CAGR and reach US$498.4 Million by the end of the analysis ... Read More
-
Pet Vaccines
... CAGR of 4.0% over the analysis period 2024-2030. Canlane, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$6.0 Billion by the end of the analysis period. ... Read More
-
Ebola Drugs and Vaccines
... 2030, growing at a CAGR of 26.1% over the analysis period 2024-2030. ZMapp, one of the segments analyzed in the report, is expected to record a 23.6% CAGR and reach US$47.0 Million by the end ... Read More
-
Chickenpox Vaccines
... CAGR of 3.9% over the analysis period 2024-2030. Monovalent Varicella Vaccine, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$2.5 Billion by the end of the ... Read More
-
Inactivated Polio and Rabies Vaccines
... Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Inactivated Polio Vaccines, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$971.3 ... Read More
-
Canine influenza Vaccines
... at a CAGR of 4.3% over the analysis period 2024-2030. Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.4 Billion by the end of ... Read More
-
Oral Typhoid Vaccines
... at a CAGR of 10.3% over the analysis period 2024-2030. Hospital Pharmacies, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$142.6 Million by the end of ... Read More
-
Preventable Vaccines
... CAGR of 1.1% over the analysis period 2024-2030. Live / Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$34.1 Billion by the end of ... Read More
-
Vaccine Contract Manufacturing
... at a CAGR of 7.4% over the analysis period 2024-2030. Attenuated, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$2.6 Billion by the end of the ... Read More
-
Therapeutic Vaccines
... CAGR of 16.7% over the analysis period 2024-2030. Autoimmune Disease Vaccines, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$62.8 Billion by the end of the ... Read More
-
Hepatitis B Vaccines
... at a CAGR of 4.3% over the analysis period 2024-2030. Adult, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$2.7 Billion by the end of the ... Read More
-
Human Vaccines
... CAGR of 7.3% over the analysis period 2024-2030. Intramuscular & Subcutaneous, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$58.7 Billion by the end of the ... Read More
-
Swine Vaccines
... CAGR of 3.7% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. ... Read More
-
Pneumococcal Vaccines
... CAGR of 5.3% over the analysis period 2024-2030. Pneumococcal Conjugate Vaccine, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$7.4 Billion by the end of the ... Read More
-
Respiratory Disease Vaccines
... at a CAGR of 0.7% over the analysis period 2024-2030. Viral Vaccine, one of the segments analyzed in the report, is expected to record a 0.6% CAGR and reach US$60.0 Billion by the end of ... Read More
Research Assistance
